CHICAGO, Oct. 28, 2024 /PRNewswire/ — Cardiosense, a digital health company developing heart failure management platforms for the early detection of worsening heart failure, today presented clinical data at the Cardiovascular Research Foundation’s 2024 annual Transcatheter Cardiovascular Therapeutics® (TCT®) scientific symposium. The presentation highlighted interim performance and demographic data on the first 500 patients enrolled in its SEISMIC-HF I clinical study to develop a novel non-invasive method for cardiac pressure estimation.
“Over a million patients with heart failure are hospitalized in the U.S. each year, accounting for more than three-quarters of an estimated $30 billion in direct medical costs. Numerous studies have shown that remote hemodynamic-guided management of patients using implanted sensors is effective at decreasing the risk of hospitalizations and mortality, and yet only a fraction of patients can use this technology,” said Amit Gupta, Co-founder and CEO of Cardiosense. “This new data marks an important milestone in our development of a non-invasive heart failure management platform aimed at democratizing specialty care to expand access to a much larger population of heart failure patients.”
The data were presented by Anjan Tibrewala, M.D. of Northwestern Medicine’s Bluhm Cardiovascular Institute as a moderated abstract presentation titled, Study Design and Interim Results of the Non-Invasive SEISMocardiogram In Cardiovascular Monitoring for Heart Failure I (SEISMIC-HF I) Study (abstract TCT-465). Interim analysis of the first 500 enrolled subjects showed successful enrollment of a large, demographically diverse population suitable for machine learning (ML). The Company also announced that enrollment in the SEISMIC-HF I study was completed and final results will be presented later this year.
TCT 2024 is being held October 27-30 at the Walter E. Washington Convention Center in Washington, DC. For the latest news and information, follow Cardiosense on X and LinkedIn, or visit: www.cardiosense.com.
About the SEISMocardiogram In Cardiovascular Monitoring for Heart Failure I (SEISMIC-HF I) Study
SEISMIC-HF I is a prospective, multi-site, observational study to collect data to develop a machine learning (ML) algorithm that estimates non-invasive pulmonary capillary wedge pressure (PCWP) from physiologic signals collected on the CardioTag™ device. The study was designed to enroll up to 1,000 participants scheduled to undergo a routine right heart catheterization (RHC) from 15 US sites. Seismocardiogram (SCG), electrocardiogram (ECG), and photoplethysmogram (PPG) waveform data and core lab-adjudicated intracardiac filling pressures were simultaneously collected on the CardioTag device and during the RHC procedure, respectively, to train the ML model.
About Cardiosense
Cardiosense is building a physiological waveform AI platform for non-invasive estimation of clinically actionable parameters to detect and manage cardiac disease. The Company has developed a suite of novel digital tools, multi-sensor devices, and analysis algorithms to detect early signs of cardiovascular disease, inform personalized therapy, and improve patient outcomes.
SOURCE Cardiosense
Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers…
CALGARY, AB / ACCESS Newswire / January 12, 2026 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an…
Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…
MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…
Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…